Earlier this month, the FDA released programmatic guidance intended to clarify the current review practices for the Humanitarian Device Exemption (“HDE”) Program (“Guidance”) reflecting recent changes in the HDE Program resulting from statutory amendments made by the 21st Century Cures. The Guidance addresses frequently asked questions about FDA actions on HDE applications, post-approval requirements, and includes a filing checklist to clarify the required information for the FDA to consider whether an HDE application is ready for substantive review.

Unlike premarket applications (“PMAs”) or De Novo Submissions, an HDE application is not required to include data that demonstrate the subject device has a reasonable assurance of effectiveness – instead the review standard requires the applicant show a probable benefit that exceeds the risk of using the device. An applicant must also demonstrate (among other things) that no similar device exists and that there is no other way to bring the device to market, and that the device would be used diagnose or treat rare diseases or conditions affecting less than 8,000 individuals in the United States per year (up from the longstanding limit of 4,000 that existed prior to passage of 21st Century Cures at the end of 2016).

The Guidance has not changed much since the June 2018 draft guidance. However, there are a few additional clarifications. For instance, the Guidance acknowledges “that investigations using laboratory animals or human subjects, as well as nonclinical investigations and analytical studies for in vitro diagnostics,” not just human subject testing may be used as evidence to support approval of an HDE application. The FDA also clarified the conditions under which an HDE can be suspended or withdrawn.

Overall, the FDA Guidance may be helpful in preparing HDE submissions, and may acknowledge additional flexibility with respect to HDE data requirements.  However, the fundamental limitations with the HDE pathway, such as limitation to very small populations and extensive post-approval requirements, remain unchanged.

Back to Health Law Advisor Blog

Search This Blog

Blog Editors


Related Services



Jump to Page


Sign up to receive an email notification when new Health Law Advisor posts are published:

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.